There are currently 2876 clinical trials in Houston, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including M D Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Baylor College of Medicine and The University of Texas - MD Anderson Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Phase III Randomized Trial Comparing Stereotactic Body Radiation Therapy (SBRT) vs Conventional Palliative Radiation Therapy for Painful Bone Metastases
NCT06065449
Recruiting
To compare increasing doses and different treatment schedules of stereotactic body radiation therapy (SBRT) against standard treatment scheduling.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Bone Metastases
Register for Updates
Enhancing the Effectiveness of Home-delivery Based Produce Prescription Program Implementation Strategies
NCT06114199
Recruiting
Harris Health System is currently participating, along with two other partners, GoldiFresh Inc., and Brighter Bites, in a cross-sector collaborative home delivery-based Produce Prescription Program (PPRx) pilot initiative that provides consistent access to healthy food plus nutrition education to Medicaid-eligible pregnant women in Harris County, TX, deemed to be at high risk of adverse pregnancy or birth outcomes. The objectives of this study are two-fold: (a) to examine utilization of food bas... Read More
Gender:
FEMALE
Ages:
Between 18 years and 44 years
Trial Updated:
07/09/2025
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Nutritional Deficiency in Pregnancy
Register for Updates
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
NCT06465953
Recruiting
This study will enroll participants with myelodysplastic syndromes (MDS) with an Isocitrate dehydrogenase protein, 1 (IDH1) mutation, who have not received treatment with a hypomethylating agent previously. Participants will be randomized to receive either ivosidenib (IVO) alone or azacitidine (AZA) alone. IVO will be administered daily throughout the 28-day treatment cycle and AZA will be administered for the first 7 days of each 28-day cycle. Study visits will be conducted every week during Cy... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: MD Anderson Cancer Centre, Houston, Texas
Conditions: Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes (MDS)
Register for Updates
Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
NCT06492291
Recruiting
This is an extension study to evaluate the longer-term safety and efficacy of enlicitide decanoate in adults with hypercholesterolemia who completed either study MK-0616-013 (NCT05952856), study MK-0616-017 (NCT05952869), or study MK-0616-018 (NCT06450366).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: Center for Cardiometabolic Disease Prevention/Baylor College of Medicine ( Site 0009), Houston, Texas
Conditions: Hypercholesterolemia
Register for Updates
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
NCT06533761
Recruiting
This is a Phase 1b open-label, multicenter, dose-escalation and dose-optimization study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor efficacy of eganelisib as monotherapy and in combination with cytarabine in patients with relapsed/refractory (r/r) acute myeloid leukemia (AML) or r/r higher-risk myelodysplastic syndromes (HR-MDS). The study consists of 2 parts: * Part 1: Dose Escalation (DE) in both monotherapy and in combination.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: AML, Adult, MDS
Register for Updates
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
NCT06564844
Recruiting
This is a Phase III, randomised, open-label, multicentre, global study assessing the efficacy and safety of adjuvant Dato-DXd in combination with rilvegostomig compared with SoC, after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponsor-designated ctDNA assay, or have at least one high-risk pathological feature.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: Research Site, Houston, Texas +1 locations
Conditions: Non-small Cell Lung Cancer
Register for Updates
Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS
NCT06680752
Recruiting
This is a phase I/2, interventional, open-label, multicenter study to assess the safety and efficacy of ARD103 in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, MDS (Myelodysplastic Syndrome)
Register for Updates
52 Week Study of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
NCT06689085
Recruiting
This is a 52-week open label single arm study to investigate the effects of XYOSTED, as testosterone replacement therapy, on adolescent males with either primary or secondary hypogonadism. The study aims to determine the effectiveness of XYOSTED measured by continuation or induction of puberty in addition to XYOSTED dosage, safety and testosterone levels.
Gender:
MALE
Ages:
Between 12 years and 17 years
Trial Updated:
07/09/2025
Locations: Texas Children's Hospital, Houston, Texas
Conditions: Hypogonadism, Male
Register for Updates
Study of 68Ga-R10602
NCT06745804
Recruiting
A phase 1 imaging study of 68Ga-R10602 in hormone-receptor positive breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Locoregionally Recurrent Hormone-receptor Positive Breast Cancer, Metastatic Hormone Receptor Positive Breast Cancer, Hormone Receptor Positive Breast Adenocarcinoma
Register for Updates
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
NCT06835569
Recruiting
The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: Research Site, Houston, Texas
Conditions: Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (non-small Cell Lung Cancer), CRC (colorectal Cancer), Advanced Solid Tumors
Register for Updates
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)
NCT06719141
Recruiting
This (DEEp OCEAN Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DEE. The study consists of 3 main phases: Screening, Titration period, Maintenance period, followed by a Taper period and Follow-Up. The total duration of the study will be approximately 24 months.
Gender:
ALL
Ages:
Between 2 years and 65 years
Trial Updated:
07/08/2025
Locations: Site Number - USA25, Houston, Texas
Conditions: Developmental and Epileptic Encephalopathy
Register for Updates
Anterior Cruciate Ligament (ACL) Reconstruction With Autologous Fat Pad Derived Mesenchymal Stem Cells
NCT06798623
Recruiting
This study is designed as a prospective, open label, single arm pilot clinical study that will establish the safety and efficacy of a single injection of mesenchymal stromal cells in patients. Each subject will receive one intra-articular injection of autologous mesenchymal stromal cells derived from infrapatellar fat pad (FP-MSC) tissue samples collected from the subject during anterior cruciate ligament (ACL) reconstruction surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: Houston Methodist Hospital, Houston, Texas
Conditions: Anterior Cruciate Ligament Reconstruction
Register for Updates